The effect of an ipriflavone-containing supplement on urinary N-linked telopeptide levels in postmenopausal women.
Osteoporosis is a significant health concern to our aging population. We report here the results of a pilot placebo-controlled trial of a dietary supplement containing ipriflavone, calcium, and vitamin D on a urinary marker of bone breakdown in postmenopausal women. Seven postmenopausal women not currently receiving hormone replacement therapy received either an ipriflavone-containing supplement or placebo for 3 months. Urinary N-linked telopeptides, a marker of bone breakdown, declined by 29% in those receiving the supplement, whereas an increase in this marker was observed in the group receiving the placebo. No changes were observed in salivary hormone measurements. Although our sample size was small, to the best of our knowledge, this is the first report that demonstrates changes in N-linked telopeptide levels as a result of consuming an ipriflavone-containing product. Our findings confirm those of other researchers that demonstrate the usefulness of ipriflavone at slowing the progression of bone loss and suggest that measuring N-linked telopeptides may be a useful tool to assess therapeutic efficacy.
Halpner
A D
AD
Douglas Laboratories, Pittsburgh, Pennsylvania 15205, USA.
Kellermann
G
G
Ahlgrimm
M J
MJ
Arndt
C L
CL
Shaikh
N A
NA
Hargrave
J J
JJ
Tallas
P G
PG
D015415:Biomarkers / Q000032:analysis / Q000652:urine*; D001862:Bone Resorption / Q000517:prevention & control / Q000652:urine; D002118:Calcium / Q000494:pharmacology / Q000627:therapeutic use; D003094:Collagen / Q000032:analysis / Q000652:urine*; D024042:Collagen Type I; D019587:Dietary Supplements; D018450:Disease Progression; D004338:Drug Combinations; D016903:Drug Monitoring; D005260:Female; D006801:Humans; D007529:Isoflavones / Q000494:pharmacology / Q000627:therapeutic use*; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000517:prevention & control*; D010455:Peptides / Q000032:analysis / Q000652:urine*; D010865:Pilot Projects; D017698:Postmenopause / Q000187:drug effects* / Q000652:urine*; D012463:Saliva / Q000737:chemistry; D014807:Vitamin D / Q000494:pharmacology / Q000627:therapeutic use
D015415:Biomarkers; D024042:Collagen Type I; D004338:Drug Combinations; D007529:Isoflavones; D010455:Peptides; C052929:collagen type I trimeric cross-linked peptide; D014807:Vitamin D; C018986:ipriflavone; D003094:Collagen; D002118:Calcium